Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 13/20 | 1.00 |
| ▸ | KDR | P35968 | 9/20 | 0.81 |
| ▸ | KIF5B | P33176 | 8/20 | 0.81 |
| ▸ | EGFR | P00533 | 5/20 | 0.73 |
| ▸ | FLT1 | P17948 | 1/20 | 0.73 |
| ▸ | RAF1 | P04049 | 1/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864594 | 0.90 | RET (1.00) | RETKDRKIF5BEGFRFLT1 | |
| SCHEMBL16785515 | 0.89 | RET (1.00) | RETKDRKIF5BEGFRFLT1 | |
| SCHEMBL16760418 | 0.89 | RET (1.00) | RETKDRKIF5BEGFRFLT1 | |
| Hydrochloric Acid SCHEMBL16760376 | 0.88 | RET (0.98) | RETKDRKIF5BEGFRFLT1 | |
| SCHEMBL16760410 | 0.88 | RET (1.00) | RETKDRKIF5BEGFRFLT1 | |
| SCHEMBL16760370 | 0.88 | RET (1.00) | RETKDRKIF5BEGFRFLT1 | |
| Hydrochloric Acid SCHEMBL16760380 | 0.87 | RET (0.98) | RETKDRKIF5BEGFRFLT1 | |
| SCHEMBL7532582 | 0.86 | RET (0.76) | RETKDRKIF5BEGFRFLT1 | |
| SCHEMBL7156156 | 0.86 | RET (0.76) | RETKDRKIF5BEGFRFLT1 | |
| SCHEMBL5864787 | 0.86 | RET (0.76) | RETKDRKIF5BEGFRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-20030149045-A1 | Therapeutic compounds | FATIH M UCKUN | 2003-08-07 | — | — | US | disclosed |
| US-6552027-B2 | 4-((3-hydroxyphenyl)amino),6,7-dimethoxy-quinazoline for example; conjugates with epidermal growth factor | PARKER HUGHES INSTITUTE | 2003-04-22 | — | — | US | disclosed |
| US-6316454-B1 | 6,7-Dimethoxy-4-anilinoquinazolines | PARKER HUGHES INSTITUTE | 2001-11-13 | — | — | US | disclosed |
| WO-2001035952-A2 | RADIOSENSITIZATION OF HUMAN GLIOBLASTOMA CELLS BY QUINAZOLINE COMPOUNDS | PARKER HUGUES INSTITUTE (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2000002576-A9 | EGF-GENISTEIN FOR PREVENTION OF RESTENOSIS | WAYNE HUGHES INST (US) | 2000-05-25 | — | — | WO | disclosed |
| US-6034053-A | VASCULAR DISORDERS | WAYNE HUGHES INSTITUTE (US) | 2000-03-07 | — | — | US | disclosed |
| WO-2000002576-A2 | EGF-GENISTEIN FOR PREVENTION OF RESTENOSIS | PARKER HUGHES INSTITUTE (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | RET 2024/4885KDR 4627/4885KIF5B 888/4885 |
| US-20030149045-A1 | Therapeutic compounds | JAK3, JAK1, JAK2 | RET 1658/4885KDR 1653/4885KIF5B 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.